Free Newsletter
ALSO NOTED: MedImmune appoints new SVP; Merck drug gets HealthCanada nod;
> MedImmune shuffled its management team last week: Andrew Skibo joined the company as senior vice president for engineering, and Dr. JoAnn Suzich was promoted to vice president of R&D-infectious disease. Release
> Health Canada gave the go-ahead to Merck's diabetes drug Januvia as an add-on treatment to metformin therapy. Report
> MGI Pharma is asking the FDA to allow it to sell a capsule form of Aloxi, an injectable drug used to treat nausea and vomiting in cancer patients. Report
> Teva Pharmaceutical Industries got the FDA nod for its generic version of DuoNeb, a bronchodilator marketed by Dey. Report
> The FDA gave its blessing to a new formulation of Sciele Pharma's high blood pressure treatment Sular. Report
And Finally... You've read our trends and predictions for the pharma industry. Now take a look back at the biotech industry in 2007 and find out what to expect in 2008. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


